融捷健康(300247) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥123,228,041.25, a decrease of 13.20% compared to ¥141,962,434.91 in the same period last year[3] - Net profit attributable to shareholders was ¥5,162,844.88, down 36.98% from ¥8,192,592.25 year-on-year[3] - The total operating revenue for Q1 2022 was CNY 123,228,041.25, a decrease of 13.2% compared to CNY 141,962,434.91 in the same period last year[16] - The total profit of CNY 19,384,707.95, up from CNY 15,969,477.59 in the same period last year, marking an increase of about 21.5%[18] - The net profit for Q1 2022 was CNY 12,373,896.73, an increase from CNY 11,742,053.34 in Q1 2021, representing a growth of approximately 5.4%[18] - The total comprehensive income attributable to the parent company was CNY 4,997,600.98, down from CNY 10,203,072.50 in Q1 2021, indicating a decrease of approximately 51.0%[18] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 32.49%, amounting to ¥6,375,180.75 compared to ¥9,442,728.18 in the previous year[3] - The cash and cash equivalents at the end of the period were CNY 83,514,872.81, down from CNY 117,053,396.37 at the end of Q1 2021, a decrease of approximately 28.7%[21] - The cash flow from investment activities was negative at CNY -13,885,986.01, compared to CNY -52,602,553.75 in the previous year, showing an improvement in cash outflow[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,020,948,318.61, a slight decrease of 0.12% from ¥1,022,175,500.47 at the end of the previous year[3] - The total liabilities decreased to CNY 147,854,364.60 from CNY 161,064,333.37 at the beginning of the year, reflecting a reduction of 8.2%[14] - The company's inventory increased to CNY 163,296,026.94 from CNY 149,163,353.47, representing a growth of 9.5%[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 41,851, with the largest shareholder holding 14.54% of the shares[8] - The total equity attributable to shareholders increased to CNY 836,337,343.17 from CNY 831,428,719.68, indicating a marginal growth[15] Expenses and Taxation - The company's financial expenses decreased significantly by 192.18%, resulting in a net financial expense of -¥61,602.19 compared to -¥787,251.65 in the previous year[7] - The income tax expense increased by 65.84% to ¥7,010,811.22, attributed to the profitability of the company's U.S. subsidiary[7] - The company reported a tax expense of CNY 7,010,811.22, which increased from CNY 4,227,424.25 in Q1 2021, reflecting a rise of approximately 65.5%[18] Accounts Receivable and R&D - Accounts receivable decreased by 44.96% to ¥18,735,743.82, primarily due to the collection of prior receivables[6] - Research and development expenses for Q1 2022 were CNY 2,667,178.09, a slight decrease from CNY 2,876,376.21 in the previous year[16] - The company reported a decrease in accounts receivable from CNY 34,042,937.80 to CNY 18,735,743.82, a reduction of 45%[13] Foreign Exchange and Other Losses - The company experienced a foreign exchange loss of CNY 301,569.91, compared to a gain of CNY 224,872.66 in the previous year[21]